Japanese Journal of Clinical Oncology 31:7-12 (2001)
© 2001 Foundation for Promotion of Cancer Research
Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic Cancer
1Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo and 2Hepatobiliary and Pancreatic Oncology Division, National Cancer Center East Hospital, Chiba, Kashiwa, Japan
Background: Gemcitabine is the most promising new agent currently being tested in pancreatic cancer. The present study was conducted to confirm the tolerability of a weekly schedule of gemcitabine at a dose of 1000 mg/m2 in Japanese patients with advanced pancreatic cancer.
Methods: The primary end-point was to evaluate the frequency of dose-limiting toxicity. Gemcitabine 1000 mg/m2 was administered over 30 min weekly in two schedules: gemcitabine x3 every 4 weeks (Schedule 1) and gemcitabine x7 followed by a week of rest and then gemcitabine x3 every 4 weeks thereafter (Schedule 2). At least three patients entered each schedule and three additional patients were treated in the presence of dose-limiting toxicity.
Results: Eleven chemo-naive patients with a good Karnofsky performance status of 
80 points and distant metastasis were entered into this trial. In Schedule 1, no dose-limiting toxicity was observed in the three patients. In Schedule 2, the evaluation of dose-limiting toxicity was complete in six of the eight enrolled patients and two patients showed dose-limiting toxicity in this Schedule; one patient experienced both grade 4 leukocytopenia and grade 4 neutropenia, and both grade 4 neutropenia and grade 3 GOT/GPT increased in another patient. Two patients (18%) showed a partial response and a clinical benefit response was also achieved in two (29%) of the seven evaluable patients.
Conclusion: Gemcitabine 1000 mg/m2 weekly x7 followed by a week of rest and weekly x3 every 4 weeks thereafter may be tolerated in Japanese patients with advanced pancreatic cancer.
+ For reprints and all correspondence: Shuichi Okada, Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5–1–1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Abbreviations: ara-C, arabinosylcytosine; DLT, dose-limiting toxicity; 5-FU, 5-fluorouracil; GEM, gemcitabine; KPS, Karnofsky performance status; PC, pancreatic cancer; UNL, upper normal limit
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Kanai, S. Matsumoto, T. Nishimura, Y. Matsumura, E. Hatano, A. Mori, T. Masui, Y. Kawaguchi, E. Nakamura, S. Tada, et al. Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy Ann. Onc., November 4, 2009; (2009) mdp513v1. [Full Text] [PDF]
|
|
|
|
|
|
M. Kanai, S. Morita, S. Matsumoto, T. Nishimura, E. Hatano, S. Yazumi, T. Sasaki, H. Yasuda, T. Kitano, A. Misawa, et al. A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia Ann. Onc., August 1, 2009; 20(8): 1397 - 1401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanaka, M. Ikeda, T. Okusaka, H. Ueno, C. Morizane, A. Hagihara, S. Iwasa, and Y. Kojima Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy Jpn. J. Clin. Oncol., November 1, 2008; 38(11): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Akaza, S. Naito, M. Usami, T. Miki, N. Miyanaga, H. Taniai, and and the Japanese Gemcitabine Study Group Efficacy and Safety of Gemcitabine Monotherapy in Patients with Transitional Cell Carcinoma after Cisplatin-Containing Therapy: A Japanese Experience Jpn. J. Clin. Oncol., April 23, 2007; (2007) hym011v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Okusaka, H. Ishii, A. Funakoshi, H. Ueno, J. Furuse, and T. Sumii A Phase I/II Study of Combination Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Cancer Jpn. J. Clin. Oncol., September 1, 2006; 36(9): 557 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Furuse, H. Ishii, T. Okusaka, M. Nagase, K. Nakachi, H. Ueno, M. Ikeda, C. Morizane, and M. Yoshino Phase I Study of Fixed Dose Rate Infusion of Gemcitabine in Patients with Unresectable Pancreatic Cancer Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 733 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ishii, J. Furuse, T. Kinoshita, M. Konishi, T. Nakagohri, S. Takahashi, N. Gotohda, K. Nakachi, E.-i. Suzuki, and M. Yoshino Treatment Cost of Pancreatic Cancer in Japan: Analysis of the Difference after the Introduction of Gemcitabine Jpn. J. Clin. Oncol., September 1, 2005; 35(9): 526 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yonemori, H. Ueno, T. Okusaka, N. Yamamoto, M. Ikeda, N. Saijo, T. Yoshida, H. Ishii, J. Furuse, E. Sugiyama, et al. Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin Clin. Cancer Res., April 1, 2005; 11(7): 2620 - 2624. [Abstract] [Full Text] [PDF]
|
|